NDAORALTABLETPriority Review
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Hypoxia-inducible Factor 2 alpha Inhibitors
Pharmacologic Class:
Hypoxia-inducible Factor Inhibitor
Clinical Trials (5)
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Started Mar 2026
450 enrolled
Von Hippel-Lindau DiseaseCarcinoma, Renal Cell
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Started Dec 2025
10 enrolled
Clear Cell Renal Cell Carcinoma
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Started Nov 2025
904 enrolled
Renal Cell Carcinoma
A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)
Started Aug 2025
14 enrolled
Healthy
A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)
Started Mar 2025
14 enrolled
Healthy
Loss of Exclusivity
LOE Date
Jun 30, 2042
198 months away
Patent Expiry
Jun 30, 2042
Exclusivity Expiry
Aug 13, 2028